Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

An Integrated In Silico Approach to Develop Epitope-Based Peptide Vaccine Against SARS-CoV-2

Author(s): Prekshi Garg, Neha Srivastava and Prachi Srivastava*

Volume 3, Issue 2, 2022

Published on: 08 February, 2021

Article ID: e080221191205 Pages: 11

DOI: 10.2174/2666796702666210208142945

Abstract

Background: SARS-CoV-2 has been a topic of discussion ever since the beginning of 2020. Every country is trying all possible steps to combat the disease ranging from shutting the complete economy of the country to the repurposing of drugs and vaccine development. The rapid data analysis and widespread tools have made bioinformatics capable of giving new insights to deal with the current scenario more efficiently through an emerging field, vaccinomics.

Objective: The present in silico study was attempted to identify peptide fragments from spike surface glycoprotein of SARS-CoV-2 that can be efficiently used for the development of an epitope- based vaccine designing approach.

Methods: The epitopes of B and T-cell are predicted using integrated computational tools. VaxiJen server, NetCTL, and IEDB tools were used to study, analyze, and predict potent T-cell epitopes, their subsequent MHC-I interactions, and B-cell epitopes. The 3D structure prediction of peptides and MHC-I alleles (HLA-C*03:03) was further made using AutoDock4.0.

Results: Based on result interpretation, the peptide sequence from 1138-1145 amino acid and sequence WTAGAAAYY and YDPLQPEL were obtained as potential B-cell and T-cell epitopes, respectively.

Conclusion: The peptide sequence WTAGAAAYY and the amino acid sequence from 1138-1145 of the spike protein of SARS-CoV-2 can be used as a probable B-cell epitope candidate. Also, the amino acid sequence YDPLQPEL can be used as a potent T-cell epitope. This in silico study will help us identify novel epitope-based peptide vaccine targets in the spike protein of SARS-CoV-2. Further, the in vitro and in vivo study needed to validate the findings.

Keywords: SARS-CoV-2, peptide vaccine, spike protein, vaccinomics, epitope prediction, immunoinformatics.

Graphical Abstract

[1]
Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 2018; 46(W1): W296-303.
[http://dx.doi.org/10.1093/nar/gky427] [PMID: 29788355]
[2]
Oany AR, Emran AA, Jyoti TP. Design of an epitope-based peptide vaccine against spike protein of human coronavirus: An in silico approach. Drug Des Devel Ther 2014; 8: 1139-49.
[http://dx.doi.org/10.2147/DDDT.S67861] [PMID: 25187696]
[3]
Bertram S, Glowacka I, Müller MA, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 2011; 85(24): 13363-72.
[http://dx.doi.org/10.1128/JVI.05300-11] [PMID: 21994442]
[4]
Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020; 71(15): 756-61.
[http://dx.doi.org/10.1093/cid/ciaa247] [PMID: 32161968]
[5]
Garg N, Singh R, Shukla G, Capalash N, Sharma P. Immunoprotective potential of in silico predicted Acinetobacter baumannii outer membrane nuclease, NucAb. Int J Med Microbiol 2016; 306(1): 1-9.
[http://dx.doi.org/10.1016/j.ijmm.2015.10.005] [PMID: 26614015]
[6]
Garrett M, Morris R H. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J Comput Chem 2009; 30(16): 2785-91.
[http://dx.doi.org/10.1002/jcc.21256] [PMID: 19399780] [PMCID: PMC2760638]
[7]
Doytchinova IA, Flower DR. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007; 8: 4.
[http://dx.doi.org/10.1186/1471-2105-8-4] [PMID: 17207271]
[8]
Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 2017; 45(W1): W24-9.
[http://dx.doi.org/10.1093/nar/gkx346] [PMID: 28472356]
[9]
Lamiable A, T P. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res 2016; 44(W1): W449-54.
[http://dx.doi.org/10.1093/nar/gkw329] [PMID: 27131374] [PMCID: PMC4987898]
[10]
Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007; 8: 424.
[http://dx.doi.org/10.1186/1471-2105-8-424] [PMID: 17973982]
[11]
Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3(1): 237-61.
[http://dx.doi.org/10.1146/annurev-virology-110615-042301] [PMID: 27578435]
[12]
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[13]
Neves MA, Totrov M, Abagyan R. Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des 2012; 26(6): 675-86.
[http://dx.doi.org/10.1007/s10822-012-9547-0] [PMID: 22569591]
[14]
McComb RC, Ho CL, Bradley KA, Grill LK, Martchenko M. Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine. Vaccine 2015; 33(48): 6745-51.
[http://dx.doi.org/10.1016/j.vaccine.2015.10.075] [PMID: 26514421]
[15]
Muhammad Tahir ul Qamar A B. Peptide vaccine against chikungunya virus: immuno-informatics combined with molecular docking approach. J Transl Med 2018; 16(1): 298.
[http://dx.doi.org/10.1186/s12967-018-1672-7] [PMID: 30368237] [PMCID: PMC6204282]
[16]
Oktavia Rahayu Adianingsih VD. Study of B cell epitope conserved region of the Zika virus envelope glycoprotein to develop multi-strain vaccine. J Appl Pharm Sci 2019; 9(1): 98-103.
[17]
Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 6: 132.
[http://dx.doi.org/10.1186/1471-2105-6-132] [PMID: 15927070]
[18]
Maurer-Stroh S, Krutz NL, Kern PS, et al. AllerCatPro-prediction of protein allergenicity potential from the protein sequence. Bioinformatics 2019; 35(17): 3020-7.
[http://dx.doi.org/10.1093/bioinformatics/btz029] [PMID: 30657872]
[19]
Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 2013; 100(3): 605-14.
[http://dx.doi.org/10.1016/j.antiviral.2013.09.028] [PMID: 24121034]
[20]
Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: Progress and Challenges. Vaccines (Basel) 2014; 2(3): 515-36.
[http://dx.doi.org/10.3390/vaccines2030515] [PMID: 26344743]
[21]
Wu JTKL, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet 2020; 395(10225): 689-97.
[http://dx.doi.org/10.1016/S0140-6736(20)30260-9] [PMID: 32014114]
[22]
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao G.F, Tan W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy